ArticleProceedings of the National Academy of Sciences of the United States of America2006
Breaking the one antibody-one target axiom.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.ACS chemical biology · 2012Pooled it
- Mechanisms of action of therapeutic antibodies for cancer.Molecular immunology · 2015Review
- Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects.Molecular pharmaceutics · 2015Article
- Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Journal of clinical pharmacology · 2015Review
- Chemically programmed antibodies.Trends in biotechnology · 2014Review
- Selective ablation of tumor-associated macrophages suppresses metastasis and angiogenesis.Cancer science · 2013Article
- Synthesis and evaluation of the aldolase antibody-derived chemical-antibodies targeting α5β1 integrin.Molecular pharmaceutics · 2013Article
- A high-throughput screening fluorescence polarization assay for fatty acid adenylating enzymes in Mycobacterium tuberculosis.Analytical biochemistry · 2011Article
- Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology.New biotechnology · 2011Review
- Chemically programmed antibodies targeting multiple alpha(v) integrins and their effects on tumor-related functions in vitro.Bioconjugate chemistry · 2011Article
- The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity.ChemMedChem · 2011Article
- A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.Journal of the American Chemical Society · 2010Article
- Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma.Nature chemical biology · 2010Article
- Designed auto-assembly of nanostreptabodies for rapid tissue-specific targeting in vivo.The Journal of biological chemistry · 2010Article
- Multiple catalytic aldolase antibodies suitable for chemical programming.Bioorganic & medicinal chemistry letters · 2009Article
- An efficient chemical approach to bispecific antibodies and antibodies of high valency.Bioorganic & medicinal chemistry letters · 2009Article
- Studies toward the duocarmycin prodrugs for the antibody prodrug therapy approach.Tetrahedron letters · 2009Article
- Targeted instant immunity.Nature biotechnology · 2009Article
- Instant immunity through chemically programmable vaccination and covalent self-assembly.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Beta-lactam-based approach for the chemical programming of aldolase antibody 38C2.Bioorganic & medicinal chemistry letters · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Studies at the interface of chemistry and biology have allowed us to develop an immunotherapeutic approach called chemically programmed antibodies (cpAbs), which combines the merits of traditional small-molecule drug design with immunotherapy. In this approach, a catalytic antibody catalyzes the covalent conjugation of a small molecule or peptide to the active site of the antibody, effectively recruiting the binding specificity of the conjugated molecule to the antibody. In essence, this technology provides the tools for breaking the "one antibody-one target axiom" of immunochemistry. Our studies in this area have focused on using the chemistry of the well studied aldolase catalytic antibodies of which mAb 38C2 is a member. Previously, we explored reversible assembly of cpAbs available through diketone chemistry. In this article, we explore a unique proadapter assembly strategy wherein an antibody 38C2-catalyzed transformation unveils a reactive tag that then reacts to form a stable covalent bond with the antibody. An integrin alpha(v)beta 3 antagonist was synthesized with the designed proadapter and studied using human breast cancer cell lines MDA-MB-231 and MDA-MB-435. We demonstrate that this approach allows for (i) the effective assembly of cpAbs in vitro and in vivo, (ii) selective retargeting of 38C2 to integrin alpha(v)beta 3 expressing breast cancer cell lines, (iii) intracellular delivery of cpAbs into cells, (iv) dramatically increased circulatory half-life, and (v) substantial enhancement of the therapeutic effect over the peptidomimetic itself in animal models of breast cancer metastasis. We believe that this technology possesses potential for the treatment and diagnosis of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.